

Hepatitis C: State of Medicaid Access Report Card

Maine



Grade	Recommendations to Improve Patient Access
C	<ul style="list-style-type: none">Remove prior authorization for HCV treatment.Remove retreatment documentation requirements.Remove additional restrictions as described below.

State Overview

As of October 2023, 370,638 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 7,000 people were living with HCV in Maine.² Maine does not contract with managed care organizations (MCO)s, and all beneficiaries are enrolled in the FFS program.³

The Maine Medicaid Preferred Drug List lists Mavyret and sofosbuvir/velpatasvir as preferred regimens.⁴

Deductions		Policy
Prior Authorization	-8	Prior authorization is required for all HCV treatment regimens.
Fibrosis Restrictions		Maine Medicaid does not impose fibrosis restrictions. ⁵
Substance Use Restrictions		Maine Medicaid does not impose substance use restrictions. ⁶
Prescriber Restrictions		Maine Medicaid does not impose prescriber restrictions for patients who are eligible for simplified treatment. ⁷
Retreatment Restrictions	-8	Maine Medicaid imposes retreatment restrictions. The prior authorization form imposes an adherence-based restriction on patients seeking retreatment: if the reason for failure was non-adherence or failure to complete therapy, the prescriber must document “what is different this time to try to improve the outcome.” ⁸
Access in Managed Care		Maine Medicaid does not contract with managed care organizations. ⁹
Additional Restrictions	-6	Maine Medicaid imposes additional restrictions as follows ¹⁰ : <ul style="list-style-type: none">Time-based lab requirements (documentation required within 6 months)Documentation of genotype14-day dispensing limitation for first fill
Total Deductions -22		Total Score [100-Deductions] 78
		Grade C

Contact Your State Officials

Medicaid Office¹¹: Michelle Probert, Director, Office of MaineCare Services

109 Capitol Street, 11 State House Station, Augusta, ME 04333; Telephone: (207) 287-2093; Email: Michelle.Probert@maine.gov

Drug Utilization Review Committee¹²: Anne-Marie Toderico, MaineCare Pharmacy Director, Office of MaineCare Services

109 Capitol Street, 11 State House Station, Augusta, ME 04333; Telephone: (207) 624-6948; Email: AnneMarie.Toderico@maine.gov

Key Sources

Preferred Drug List: [Maine Medicaid, Preferred Drug List \(Feb. 22, 2024\)](#)

Prior Authorization Form: [Maine Medicaid, Hepatitis C Treatment Prior Authorization Form \(Dec. 2023\)](#)

-
- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Maine, <https://perma.cc/CY7M-UAWF>.
- ² HepVu, Local Data: Maine State Profile, <https://perma.cc/7V7N-BZPJ>.
- ³ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2022), <https://perma.cc/EMN8-QR8B>.
- ⁴ Preferred Drug List.
- ⁵ Prior Authorization Form.
- ⁶ Prior Authorization Form.
- ⁷ Prior Authorization Form.
- ⁸ Prior Authorization Form.
- ⁹ Kaiser Family Foundation, Annual Medicaid Budget Survey for State Fiscal Years 2023 and 2024, Kaiser Family Foundation (Nov. 14, 2023), <https://perma.cc/4K6Y-8DEM>.
- ¹⁰ Prior Authorization Form.
- ¹¹ National Association of Medicaid Directors, Medicaid Directors, <https://perma.cc/7KTL-ULKZ>.
- ¹² MaineCare Services, Contact Information, <http://www.mainearepdl.org/content/contact-information>.